Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;112(5):1285-1295.
doi: 10.1002/JLB.5VMR0322-161R. Epub 2022 Aug 31.

Animal models for studies of HIV-1 brain reservoirs

Affiliations
Review

Animal models for studies of HIV-1 brain reservoirs

Emiko Waight et al. J Leukoc Biol. 2022 Nov.

Abstract

The HIV-1 often evades a robust antiretroviral-mediated immune response, leading to persistent infection within anatomically privileged sites including the CNS. Continuous low-level infection occurs in the presence of effective antiretroviral therapy (ART) in CD4+ T cells and mononuclear phagocytes (MP; monocytes, macrophages, microglia, and dendritic cells). Within the CNS, productive viral infection is found exclusively in microglia and meningeal, perivascular, and choroidal macrophages. MPs serve as the principal viral CNS reservoir. Animal models have been developed to recapitulate natural human HIV-1 infection. These include nonhuman primates, humanized mice, EcoHIV, and transgenic rodent models. These models have been used to study disease pathobiology, antiretroviral and immune modulatory agents, viral reservoirs, and eradication strategies. However, each of these models are limited to specific component(s) of human disease. Indeed, HIV-1 species specificity must drive therapeutic and cure studies. These have been studied in several model systems reflective of latent infections, specifically in MP (myeloid, monocyte, macrophages, microglia, and histiocyte cell) populations. Therefore, additional small animal models that allow productive viral replication to enable viral carriage into the brain and the virus-susceptible MPs are needed. To this end, this review serves to outline animal models currently available to study myeloid brain reservoirs and highlight areas that are lacking and require future research to more effectively study disease-specific events that could be useful for viral eradication studies both in and outside the CNS.

Keywords: CNS; HIV-1; animal models; brain; humanized mice; myeloid reservoir.

PubMed Disclaimer

References

    1. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49‐62. - PubMed
    1. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral‐naive adults with HIV‐1 infection (GEMINI‐1 and GEMINI‐2): week 48 results from two multicentre, double‐blind, randomised, non‐inferiority, phase 3 trials. Lancet. 2019;393:143‐155. - PubMed
    1. Siliciano JD, Kajdas J, Finzi D, et al. Long‐term follow‐up studies confirm the stability of the latent reservoir for HIV‐1 in resting CD4+ T cells. Nat Med. 2003;9:727‐8. - PubMed
    1. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV‐1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193‐7. - PMC - PubMed
    1. Lorenzo‐Redondo R, Fryer HR, Bedford T, et al. Persistent HIV‐1 replication maintains the tissue reservoir during therapy. Nature. 2016;530:51‐56. - PMC - PubMed

Publication types

Substances